Efficacy and Prognosis of First-Line EGFR-Tyrosine Kinase Inhibitor Treatment in Older Adults Including Poor Performance Status Patients with EGFR-Mutated Non-Small-Cell Lung Cancer

Cancer Management and Research ◽

10.2147/cmar.s322967 ◽

2021 ◽

Vol Volume 13 ◽

pp. 7187-7201

Author(s):

Cheng-Yu Chang ◽

Chung-Yu Chen ◽

Shih-Chieh Chang ◽

Yi-Chun Lai ◽

Yu-Feng Wei

Keyword(s):

Kinase Inhibitor ◽

Performance Status ◽

Poor Performance ◽

Small Cell ◽

Poor Performance Status ◽

Small Cell Lung ◽

First Line ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Mutated ◽

Inhibitor Treatment

Download Full-text

Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study

Journal of Cancer ◽

10.7150/jca.30507 ◽

2019 ◽

Vol 10 (17) ◽

pp. 4151-4158

Author(s):

Yu-Feng Wei ◽

Wen-Tsung Huang ◽

Tu-Chen Liu ◽

Jiunn-Min Shieh ◽

Chih-Feng Chian ◽

...

Keyword(s):

Quality Of Life ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Egfr Tyrosine Kinase Inhibitor ◽

Factors Associated ◽

Egfr Mutated ◽

Inhibitor Treatment

Download Full-text

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-19-1126 ◽

2019 ◽

Vol 25 (22) ◽

pp. 6644-6652 ◽

Cited By ~ 18

Author(s):

Jhanelle E. Gray ◽

Isamu Okamoto ◽

Virote Sriuranpong ◽

Johan Vansteenkiste ◽

Fumio Imamura ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Mutated ◽

First Line Treatment

Download Full-text

Paclitaxel Poliglumex/Carboplatin Is Similar to Paclitaxel/Carboplatin as First-Line Treatment in Elderly Patients with Advanced Non–Small-Cell Lung Cancer and a Poor Performance Status

Clinical Lung Cancer ◽

10.1016/s1525-7304(11)70386-2 ◽

2005 ◽

Vol 7 (1) ◽

pp. 20-22

Author(s):

G. Kesava Reddy ◽

Chandra P. Belani ◽

Vinay K. Jain

Keyword(s):

Lung Cancer ◽

Elderly Patients ◽

Performance Status ◽

Poor Performance ◽

Small Cell ◽

Poor Performance Status ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

First Line Treatment

Download Full-text

PCN109 Cost Effectiveness of First Line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: A Markov Model

Value in Health ◽

10.1016/j.jval.2011.08.1210 ◽

2011 ◽

Vol 14 (7) ◽

pp. A454 ◽

Cited By ~ 2

Author(s):

I. Borget ◽

A. Vergnenegre ◽

C. Chouaid

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

Nsclc Patients ◽

Egfr Mutated ◽

Inhibitor Treatment

Download Full-text

The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status

Lung Cancer ◽

10.1016/j.lungcan.2010.12.006 ◽

2011 ◽

Vol 73 (2) ◽

pp. 203-210 ◽

Cited By ~ 15

Author(s):

Shan Liu ◽

Deqiang Wang ◽

Bo Chen ◽

Yan Wang ◽

Weihong Zhao ◽

...

Keyword(s):

Performance Status ◽

Single Agent ◽

Poor Performance ◽

Small Cell ◽

Poor Performance Status ◽

Small Cell Lung ◽

First Line ◽

Single Agent Chemotherapy ◽

Egfr Tkis ◽

First Line Treatment

Download Full-text

Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients and patients with poor performance status who have extensive-stage small cell lung carcinoma

Cancer ◽

10.1002/cncr.20281 ◽

2004 ◽

Vol 100 (11) ◽

pp. 2437-2441 ◽

Cited By ~ 18

Author(s):

John D. Hainsworth ◽

Donna Carrell ◽

Ronald L. Drengler ◽

Carroll Scroggin ◽

F. Anthony Greco

Keyword(s):

Small Cell Lung Carcinoma ◽

Performance Status ◽

Poor Performance ◽

Small Cell ◽

Poor Performance Status ◽

Small Cell Lung ◽

First Line ◽

Cell Lung Carcinoma ◽

Extensive Stage ◽

First Line Treatment

Download Full-text

A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer

Lung Cancer ◽

10.1016/j.lungcan.2008.12.017 ◽

2009 ◽

Vol 66 (1) ◽

pp. 97-102 ◽

Cited By ~ 9

Author(s):

L. Johnetta Blakely ◽

Lee Schwartzberg ◽

Mark Keaton ◽

Fred Schnell ◽

David Henry ◽

...

Keyword(s):

Lung Cancer ◽

Phase Ii Trial ◽

Performance Status ◽

Poor Performance ◽

Small Cell ◽

Poor Performance Status ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy

Download Full-text

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status

Journal of Thoracic Oncology ◽

10.1097/jto.0b013e3181cee1ea ◽

2010 ◽

Vol 5 (3) ◽

pp. 361-368 ◽

Cited By ~ 14

Author(s):

Young Joo Lee ◽

Heung Tae Kim ◽

Ji-Youn Han ◽

Tak Yun ◽

Geon Kook Lee ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Performance Status ◽

Poor Performance ◽

Small Cell ◽

Poor Performance Status ◽

Small Cell Lung ◽

First Line ◽

Gefitinib Treatment

Download Full-text

Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301)

Journal of Geriatric Oncology ◽

10.1016/j.jgo.2015.02.002 ◽

2015 ◽

Vol 6 (3) ◽

pp. 233-240 ◽

Cited By ~ 4

Author(s):

Gaetan Des Guetz ◽

Thierry Landre ◽

Virginie Westeel ◽

Bernard Milleron ◽

Fabien Vaylet ◽

...

Keyword(s):

Phase Ii Trial ◽

Performance Status ◽

Survival Rates ◽

Poor Performance ◽

Small Cell ◽

Poor Performance Status ◽

Small Cell Lung ◽

First Line ◽

Randomized Phase Ii ◽

Similar Survival

Download Full-text

P2-316: Phase II trial of pemetrexed and gemcitabine as first-line chemotherapy for elderly and/or poor performance status patients with stage iiib/iv non-small cell lung cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000284024.75029.ab ◽

2007 ◽

Vol 2 (8) ◽

pp. S699

Author(s):

Lee S. Schwartzberg ◽

Johnetta Blakely ◽

Mark Keaton ◽

Fred Schnell ◽

David Henry ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii Trial ◽

Performance Status ◽

Poor Performance ◽

Small Cell ◽

Poor Performance Status ◽

Small Cell Lung ◽

First Line ◽

Line Chemotherapy

Download Full-text